Melphalan and dexamethasone for patients with multiple myeloma who are not candidates for autologous stem cell transplantation

作者：Sharma Atul^*; Lokeshwar Nilesh; Raina Vinod; Mohanti Bidhu K; Kumar Rajive

来源：National Medical Journal of India, 2007, 20(3): 121-124.

Background. Multiple myeloma is a disease for which a number of treatment options are available. The choice of therapy is often based on factors such as cost, ease of administration and faster response as the survival rates are similar with most of the regimens. We assessed the efficacy of a combination of melphalan and dexamethasone as first-line therapy in patients with multiple myeloma who were not candidates for autologous stem cell transplantation.
Methods. Thirty-four patients with multiple myeloma were included in the study. Patients received a maximum of 12 cycles of chemotherapy consisting of oral melphalan 8 mg/m(2) on days 1-4 and oral dexamethasone 40 mg on days 1-4 and days 9-12 every 4 weeks. Patients were assessed for response on the basis of M proteins and a bone marrow biopsy with touch preparation.
Results. The median follow up of surviving patients was 40 months. Nine patients (26.1 %) had complete response/near complete response (5 had negative immunofixation) and 15 (44%) had partial response. The regimen was well tolerated and there were no therapy-related deaths. The 3-year overall and progression-free survival rates using the Kaplan-Meier method were 53% and 34%, respectively. The median duration of overall and progression-free survivals were 58 and 28 months, respectively.
Conclusion. The combination of melphalan and dexamethasone is safe and effective in patients with multiple myeloma who are not candidates for autologous stem cell transplantation.

• 出版日期2007-6
• 单位河北医科大学